Burdon J, Conway S P, Murchan P, Lansdown M, Kester R C
Regional Adult Cystic Fibrosis Unit, St. James' University Hospital, Leeds, UK.
Eur Respir J. 1998 Jul;12(1):212-6. doi: 10.1183/09031936.98.12010212.
An implantable venous access system provides a reliable and painless entry site for intravenous treatment. This study reports the authors' experience with such a system in adult patients with cystic fibrosis. Sixty five (87%) of 75 PAS Ports were placed successfully in 57 patients with cystic fibrosis. Because of early difficulties in advancing the catheter in patients whose veins had been traumatized by repeated courses of intravenous antibiotics, a technique was developed whereby venous entry was gained by direct subclavian puncture. This catheter insertion method was used in 53 (82%) attempts and the catheter was then passed by subcutaneous tunnelling to the port site on the ventral aspect of the upper arm. Fifty seven (88%) insertions were successful under local anaesthetic. The major early and late complications were iatrogenic pneumothorax (six cases) and infection (five cases), respectively. Late complications were more common when there was coexisting disease, e.g. diabetes mellitus, or an acute severe respiratory exacerbation, or when the Port was used for parenteral feeding. In conclusion, the PAS Port can be inserted safely by direct subclavian puncture. It was well tolerated and universally liked by the patients.
植入式静脉通路系统为静脉治疗提供了一个可靠且无痛的进入部位。本研究报告了作者在成年囊性纤维化患者中使用这种系统的经验。75个PAS端口中的65个(87%)成功植入了57例囊性纤维化患者体内。由于在接受反复静脉抗生素治疗而导致静脉受损的患者中,早期在推进导管时遇到困难,因此开发了一种通过直接锁骨下穿刺获得静脉通路的技术。在53次(82%)尝试中使用了这种导管插入方法,然后通过皮下隧道将导管送至上臂腹侧的端口部位。57次(88%)插入在局部麻醉下成功完成。主要的早期和晚期并发症分别是医源性气胸(6例)和感染(5例)。当存在合并疾病,如糖尿病,或急性严重呼吸加重,或端口用于肠外营养时,晚期并发症更常见。总之,PAS端口可通过直接锁骨下穿刺安全插入。患者对其耐受性良好且普遍满意。